Cargando…

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

BACKGROUND: Breast cancer mainly occurs in young and premenopausal women; its incidence is increasing annually. Patients with triple-negative breast cancer (TNBC) have relatively high recurrence and transfer rates during the operation and 3 years after postoperative adjuvant chemotherapy. Currently,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Feng, Chen, Ru-Yue, Hou, Jun, Guo, Jing, Dong, Tian-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100709/ https://www.ncbi.nlm.nih.gov/pubmed/35647172 http://dx.doi.org/10.12998/wjcc.v10.i12.3698

Ejemplares similares

Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography
por: Pan, Hong-Yu, et al.
Publicado: (2022)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients
por: Ke, Zi-Rui, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy
por: Zhu, Yue-Lu, et al.
Publicado: (2019)

Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery
por: Lin, Wei-Xun, et al.
Publicado: (2022)

Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes
por: Liu, Yi, et al.
Publicado: (2018)

Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
por: Li, Zheng-Yan, et al.
Publicado: (2020)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
por: Li, Yang, et al.
Publicado: (2020)

Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study
por: Liu, Wei, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients
por: Asghar, Kashif, et al.
Publicado: (2020)

Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children
por: He, Min, et al.
Publicado: (2022)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
por: Reggiani Bonetti, Luca, et al.
Publicado: (2017)

Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study
por: He, Yong-Gang, et al.
Publicado: (2022)

Short and long-term outcomes between laparoscopic and open total gastrectomy for advanced gastric cancer after neoadjuvant chemotherapy
por: Cui, Hao, et al.
Publicado: (2022)

Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer
por: Tang, Rui, et al.
Publicado: (2023)

Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer
por: Li, Wen-Chang, et al.
Publicado: (2021)

Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis
por: Chen, Yu-Rui, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy
por: Serayssol, Chloé, et al.
Publicado: (2019)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
por: Suzuki, Kosuke, et al.
Publicado: (2021)

Retrospective review of total neoadjuvant therapy
por: Babar, Laila, et al.
Publicado: (2019)

Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis
por: Bai, Sai-xi, et al.
Publicado: (2020)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer
por: Ren, Dong-Lin, et al.
Publicado: (2019)

Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis
por: Li, Yunhai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_akrbk7fd4nod04hrsv49bpkgej